HIROSHI URESHINO

Last Updated :2024/07/05

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, Associate Professor
E-mail
hureshinhiroshima-u.ac.jp
Self-introduction
We developed new orally available DNMT1 inhibitor. The dug can regulate CML stem cell for CML cure. We investigate KIR or cancer specific epitope for treatment-free remission in patients with CML.

Basic Information

Major Professional Backgrounds

  • 2024/08/01, Saga University Drug Discovery and Biomedical Sciences, Professor
  • 2023/08/01, Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Associate Professor
  • 2022/04/01, 2023/07/31, Hiroshima University Research Institute for Radiation Biology and Medicine, Associate Professor
  • 2020/01/01, 2022/03/31, Saga University Hematology and Oncology, Lectuer
  • 2017/04/01, 2019/12/31, Saga University Drug Discovery and Biomedical Sciences, Assistant Professor
  • 2015/04/01, 2017/03/31, Saga University Hematology and Oncology, Fellow
  • 2011/04/01, 2015/03/31, Karatsu red cross hospital internal medicine, Medical doctor
  • 2008/04/01, 2011/03/31, Kakarashima-clinic, Chief
  • 2006/04/01, 2008/03/31, Saga Prefectural hospital, Resident

Academic Degrees

  • Saga University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Hematology

Research Keywords

  • Tageting SLAMF7 by DNA demethylating agent in MM.
  • CML stem cell
  • Treatment- free remission in patients with CML
  • Polymorphisms of killer immunoglobulin-like receptor
  • Development of new DNMT inhibitor
  • AML/MDS
  • Chronic myeloid leukemia

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Clinical diagnosis and treatment II
  2. 2024, Undergraduate Education, First Semester, Internal Medicine II
  3. 2024, Graduate Education (Doctoral Program) , 1Term, Principles of Oncology

Research Activities

Academic Papers

  1. Spontaneous Regression of Methotrexate-related Lymphoproliferative Disorder with T-cell Large Granular Lymphocytosis, Internal Medicine, 20150915
  2. Rituximab-containing Chemotherapy(R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma, Internal Medicine, 20151215
  3. Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia, Annals of Hematology, 20160401
  4. Acute Megakaryoblastic Leukemia with Myelodysplasia-related Changes Associated with ATM Gene Deletion, Internal Medicine, 20160601
  5. ★, Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia, Cancer Immunology Research, 20160601
  6. Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma, Internal Medicine, 20160801
  7. Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, Internal Medicine, 20160901
  8. Unusual co-occurrence of Evans syndrome and pure red cell aplasia in elderly patient with prostate cancer, Annals of Hematology, 20161001
  9. 5q− syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10), International journal of Hematology, 20170501
  10. Paraneoplastic Sarcoidosis in Multiple Myeloma, Internal Medicine, 20170801
  11. Steroid-Refractory Autoimmune Hemolytic Anemia with Massive Splenomegaly, American journal of Medicine, 20170901
  12. Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients, Annals of Hematology, 20170901
  13. Persistent Gastrointestinal Angiodysplasia in Heyde's Syndrome after Aortic Valve Replacement), Internal Medicine, 20170901
  14. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma, Hematological Oncology, 20180201
  15. Sustained ventricular tachycardia caused by subacute thyroiditis, Internal Medicine Journal, 20180201
  16. Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia, Oncoimmunology, 20180304
  17. Primary effusion lymphoma-like lymphoma with a T cell phenotype, Annals of Hematology, 20180401
  18. Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma, International Journal of Hematology, 20180601
  19. ★, Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML, Cancer Immunology Research, 20180601
  20. Rectal MALT lymphoma regression and anti-Helicobacter pylori therapy, QJM, 20181001
  21. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma, Annals of Hematology, 20190201
  22. Timing of surgical interventions for upper cervical epidural abscess: a case report and review of the literature., European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 20190301
  23. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma., Clinical lymphoma, myeloma & leukemia, 20190301
  24. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis., Annals of Hematology, 20190501
  25. Treatment choice for primary rectal MALT lymphoma, QJM, 20190801
  26. ★, Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib, Lancet Haematology, 20191001
  27. ★, Role of Cancer Immunology in Chronic Myelogenous Leukemia, Leukemia Research, 20191101
  28. Clinical impact of the CONUT score in patients with multiple myeloma, Annals of Hematology, 20191101
  29. ★, Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial, Lancet Haematology, 20200301
  30. ★, Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation., Int J Hematol, 111(5), 733-738, 20200501
  31. ★, Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis using the new oral demethylating agent OR-2100, BLOOD, 20200511
  32. Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?, International Journal of Hematology, 20200601
  33. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy, International Journal of Hematology, 20200601
  34. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors, International Journal of Hematology, 20200701
  35. Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia, Immunological Medicine, 20200725
  36. Vascular events may predict the prognosis of patients with chronic myeloid leukemia, International Journal of Hematology, 20200801
  37. A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation., Annals of Hematology, 20200826
  38. Multiple myeloma with G-CSF production mimicking chronic neutrophilic leukemia., eJHaem, 20210309
  39. ★, HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia, Molecular Cancer Therapeutics, 20201020
  40. Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome., Internal Medicine, 20210101
  41. Dasatinib-Blinatumomab for Ph-Positive ALL., The New England journal of medicine, 20210128
  42. Treatment strategy for upper cervical epidural abscess: a literature review, Nagoya Journal of Medical Science, 20210201
  43. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute., International Journal of Hematology, 20210427
  44. ★, Treatment-free remission and immunity in chronic myeloid leukemia., International Journal of Hematology, 20210501
  45. ★, Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience., Hematological Oncology, 20210611
  46. Pain relief differentiated according to the length of time that preoperative skin traction was carried out for hip fractures: A systematic review and meta-analysis, International Journal of Orthopaedic and Trauma Nursing, 20210801
  47. ★, Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects., Molecular Cancer Therapeutics, 20210801
  48. Immune dysregulation syndrome with CTLA4 mutation showing multiple central nervous system lesions, Clinical and Experimental Neuroimmunology, 20210823
  49. J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors., International Journal of Hematology, 112(3), 429-430, 20210901
  50. Immune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman, Cureus, 13(9), e17942, 20210913
  51. Helicobacter cinaedi bacteremia in a patient with primary central nervous system lymphoma, eJHaem, 2(4), 875-876, 20210916
  52. ★, Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial., Lancet Haematology, 8(12), e902-e911, 20211201
  53. ★, Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia, Cancer Letters, 526, 273-283, 20220201
  54. Coexistence of gastric and pulmonary MALT lymphoma and a clonally related, disseminated large B cell lymphoma with conspicuous angiotropism., Annals of Hematology, 101, 1383-1385, 20220223
  55. ★, Adult T cell leukemia lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism, International Journal of Cancer, 150(7), 1184-1197, 20220401
  56. ★, Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia, Indian Journal of Hematology and Blood Transfusion, 38(4), 760-761, 20220418
  57. Alveolar rhabdomyosarcoma with massive bone marrow infiltration and disseminated intravascular coagulation mimicking acute leukemia, eJHaem, 3(3), 1062-1063, 20220518
  58. Eosinophilic cystitis mimicking hemorrhagic cystitis in relapsed follicular lymphoma, International Cancer Conference Journal, 11(4), 298-301, 20220721
  59. Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis, Leukemia & Lymphoma, 63(14), 3511-3512, 20220913
  60. Diffuse Large B-cell Lymphoma Involving an Abundant Infiltration of T Follicular Helper Cells: A Case Report, Intern Med, 62(9), 1335-1340, 20220921
  61. Vitreoretinal Lymphoma in a Patient with Rheumatoid Arthritis with a History of Methotrexate-associated Lymphoproliferative Disorders., Ocul Immunol Inflamm., 16, 20221117
  62. ★, Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia, Hematology, 27(1), 1171-1175, 20221103
  63. ★, Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL, BLOOD adv, 7(8), 1545-1559, 20221215
  64. Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL rearranged complex karyotype acute myeloid leukemia, eJHaem, 4(1), 273-275, 20221226
  65. Late graft failure with donor-derived GPI-deficient cells in a mixed chimera following allogeneic bone marrow transplantation for severe aplastic anemia, Bone Marrow Transplantation, 58(4), 465-468, 20230121
  66. Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia, CANCER RESEARCH COMMUNICATIONS, 3(2), 297-308, 20230221
    Link to Paper Search Results by DOI
  67. Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia, CUREUS JOURNAL OF MEDICAL SCIENCE, 15(5), e39481, 20230525
    Link to Paper Search Results by DOI
  68. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia, INVESTIGATIONAL NEW DRUGS, 41(5), 751-760, 202310
    Link to Paper Search Results by DOI
  69. ★, A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation, Cancers, 15(20), 5089, 202310
  70. Challenging Diagnosis of Lytic Bone Lesions Between Multiple Myeloma and Bone Metastasis of Primary Breast Cancer, CUREUS JOURNAL OF MEDICAL SCIENCE, 15(11), e48880, 20231116
    Link to Paper Search Results by DOI
  71. Efficacy of Low-Level Laser Therapy for Oral Mucositis in Hematologic Patients Undergoing Transplantation: A Single-Arm Prospective Study, JOURNAL OF PERSONALIZED MEDICINE, 13(11), 1603, 202311
    Link to Paper Search Results by DOI
  72. Facial nerve palsy and hypopituitarism associated with immunoglobulin G4-related disease in an elderly man, 20231126
  73. ★, KIR3DL1-HLA-Bw status is associated with Achievement of TFR in CML: the POKSTIC Trial, a Multicentre Observational Study, BLOOD neoplasia, 202401
  74. Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells, BLOOD adv, 202401
  75. ★, Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia, Clin Lymphoma Myeloma Leuk, 24(4), e138-e141, 202404
  76. ★, DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis, Leukemia, 20240605
  77. ★, A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment, Clinics and Practice, 14(4), 1216-1224, 202406
  78. Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute, Blood Cells, Molecules, and Diseases, 108, 102870, 202409
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly- Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial., Kumagai T, Murai K, Ureshino H, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Mita M, Uoshima N, Kiguchi T, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S., 2021 ASH ANNUAL MEETING Atlanta, GA, USA, 2021/12/11, Without Invitation, English
  2. JSH-EHA Joint Session Development topics of Ph positive leukemia, Hiroshi Ureshino, The 12th JSH International Symposium 2021 in Kamakura, 2021/05/14, With Invitation, English
  3. BIOLOGICAL SIGNIFICANCE OF UCK2 IN HTLV-1-INFECTED CELLS IN ATL LEUKEMOGENESIS AND ACQUIRED RESISTANCE TO AZACITIDINE, Tatsuro Watanabe, Yuta Yamamoto , Kazuharu Kamachi , Yuki Kurahashi , Nao Yoshida-Sakai , Hiroshi Ureshino , Yuki Fukuda-Kurahashi , Hideaki Nakamura , Eisaburo Sueoka , Shinya Kimura, 2022 EHA congress, 2022/06, Without Invitation, English, The European Hematology Association, Austria (Hybrid)
  4. THE POTENTIAL USE OF AN ORAL HYPOMETHYLATING AGENT, OR-2100, AS A COMBINATION THERAPY FOR MYELOID MALIGNANCIES, Kazuharu Kamachi, Hiroshi Ureshino , Kazunori Kawasoe , Nao Yoshida-Sakai , Yuta Yamamoto , Yuki Fukuda-Kurahashi , Yuki Kurahashi , Tatsuro Watanabe , Shinya Kimura, 2022 EHA congress, 2022/06, Without Invitation, English, The European Hematology Association, Austria (Hybrid)
  5. Successful TKI discontinuation at the attempt in patients with CML associated with neutrophil counts, The 84th Annual Meeting of the Japanese Society of Hematology, 2022/10/16, Without Invitation, Japanese, Japanese Society of Hematology, Fukuoka(Hybrid)
  6. Type II cyroglobulinemic membranoproliferative glomerulonephritis caused by MALT lymphoma, The 84th Annual Meeting of the Japanese Society of Hematology, 2022/10/16, Without Invitation, Japanese, Japanese Society of Hematology, Fukuoka(Hybrid)
  7. An oral combination therapy of OR2100 and venetoclax in acute myeloid leukemia, The 84th Annual Meeting of the Japanese Society of Hematology, 2022/10/16, Without Invitation, Japanese, Japanese Society of Hematology, Fukuoka(Hybrid)
  8. Efficacy of standard and intensive therapy in aged patients with double-/triple-expressor lymphoma, The 84th Annual Meeting of the Japanese Society of Hematology, 2022/10/16, Without Invitation, Japanese, Japanese Society of Hematology, Fukuoka(Hybrid)
  9. P654: ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY, Ureshino, Hiroshi1; Ueda, Yasunori2; Fujisawa, Shin3; Usuki, Kensuke4; Tanaka, Hideo5; Okada, Masaya6; Kowata, Shugo7; Murai, Kazunori8; Hirose, Asao9; Shindo, Motohiro10; Kumagai, Takashi11; Nakao, Takafumi12; Takeoka, Tomoharu13; Kamachi, Kazuharu14; Kidoguchi, Keisuke14; Iyama, Satoshi15; Inamura, Junki16; Kobayashi, Tsutomu17; Kawata, Eri18; Ohkawara, Hiroshi19; Ikezoe, Takayuki19; Kimura, Shinya, EHA2023 Hybrid Congress, 2023/06/09, Without Invitation, English, EHA, Frankfurt
  10. P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA, Kazuharu Kamachi, Hiroshi Ureshino, Kazunori Kawasoe, Keisuke Kidoguchi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Yuki Kurahashi, Tatsuro Watanabe, Shinya Kimura, 2023 EHA Hybrid Congress, Without Invitation, English, EHA, Frankfurt
  11. P1233: TUMOR PREVENTION USING DNA DEMETHYLATING AGENTS ON VIRUS-DERIVED CARCINOGENESIS IN MICE., Yuta Yamamoto, Tatsuro Watanabe, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Satoshi Yamashita, Naoko Hattori, Toshikazu Ushijima, Shinya Kimura, EHA2023 Hybrid Congress, 2023/06, Without Invitation, English, EHA
  12. P1236: REGULATION OF DNA AND HISTONE METHYLATION THROUGH METHIONINE METABOLISM IN ATL LEUKEMOGENESIS, Tatsuro Watanabe, Sho Kitamura, Keita Kai, Satoshi Yamashita, Naoko Hattori, Yuta Yamamoto, Kazuharu Kamachi, Yuki Kurahashi, Hiroshi Ureshino, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Akemi Sato, Seiji Okada, Toshikazu Ushijima, Eisaburo Sueoka, Shinya Kimura, EHA2023 Hybrid Congress, 2023/06, Without Invitation, Japanese, EHA

Patented

  1. Patent, 第7228169号
  2. Patent, 7105460, 2022/07/14
  3. Patent, 6956937, 2021/10/08

External Funds

Acceptance Results of Competitive Funds

  1. 2021/04/01, 2025/03/31
  2. 2019/04/01, 2021/03/31